The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Second-line chemotherapy efficacy in patients with previously treated advanced thymic carcinoma: A retrospective analysis of 192 patients from NEJ023 Study.
 
Shunichiro Iwasawa
No Relationships to Disclose
 
Ryo Ko
Honoraria - AstraZeneca Japan; Boehringer Ingelheim
 
Takehito Shukuya
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Pfizer
 
Satoshi Watanabe
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer
 
Yoko Tsukita
No Relationships to Disclose
 
Hironori Ashinuma
No Relationships to Disclose
 
Taku Nakagawa
No Relationships to Disclose
 
Ryo Ito
No Relationships to Disclose
 
Kazutsugu Uematsu
No Relationships to Disclose
 
Mika Nakao
No Relationships to Disclose
 
Yoshiaki Mori
No Relationships to Disclose
 
Kyoichi Kaira
No Relationships to Disclose
 
Atsuto Mouri
No Relationships to Disclose
 
Takao Miyabayashi
No Relationships to Disclose
 
Hiroyuki Sakashita
Honoraria - Boehringer Ingelheim; Chugai Pharma; Nobelpharma; Pfizer; Taiho Pharmaceutical
 
Yoko Matsumoto
No Relationships to Disclose
 
Tomoyuki Tanigawa
No Relationships to Disclose
 
Satoshi Morita
No Relationships to Disclose
 
Kazuhisa Takahashi
Research Funding - Astellas Pharma (Inst); AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyorin (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)